CONSTIPATION TREATMENT MARKET ANALYSIS
Key Developments in the constipation treatment market
Key players in the market are focused on gaining product approvals from regulatory bodies to expand their product portfolio. For instance, in December 2018, the U.S. FDA approved Prucalopride, a selective serotonin-4 (5-HT4) receptor agonist that is administered as a once-daily, oral treatment for chronic idiopathic constipation, developed by Shire Plc., U.S-registered specialty biopharmaceutical company.
Major market players are also focused on conducting clinical trials. For instance, in May 2019, DuPont de Nemours, Inc. published results of a randomized, controlled trial that assessed the impact of lactitol and psyllium on bowel function in constipated Indian volunteers.
However, product recall in some regions is expected to hider the market growth. For instance, in August 2019, the UAE Ministry of Health and Prevention issued a circular on noting the withdrawal of Laxocodyl suppositories batch used for the treatment of constipation in adults, produced by JulpharGulf Pharmaceutical Industries, as a result of incorrect labeling.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
